Coherus Oncology, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Coherus Oncology, Inc. (CHRS) reported Revenue from Contract with Customer, Excluding Assessed Tax of $123.86 million for the 3-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2020-02-27
- Coherus Oncology, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-12-31 was $123.86M.
- Coherus Oncology, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-09-30 was $111.68M.
- Coherus Oncology, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-06-30 was $83.43M.
- Coherus Oncology, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-03-31 was $37.10M.
- Coherus Oncology, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Coherus Oncology, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2017 was $1.56M, a 99.18% decline from fiscal 2016.
- Coherus Oncology, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2016 was $189.48M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2019-12-31 | $123.86M 10-K · filed 2020-02-27 | $235.54M derived: sum of 2 quarters · filed 2020-02-27 | $318.97M derived: sum of 3 quarters · filed 2020-02-27 | $356.07M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-09-30 | $111.68M 10-K · filed 2020-02-27 | $195.12M derived: sum of 2 quarters · filed 2020-02-27 | $232.22M derived: sum of 3 quarters · filed 2020-02-27 | $232.22M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | $83.43M 10-K · filed 2020-02-27 | $120.53M derived: sum of 2 quarters · filed 2020-02-27 | $120.53M derived: sum of 3 quarters · filed 2020-02-27 | $120.53M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | $37.10M 10-K · filed 2020-02-27 | $37.10M derived: sum of 2 quarters · filed 2020-02-27 | $37.10M derived: sum of 3 quarters · filed 2020-02-27 | $37.10M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 10-K · filed 2019-02-28 |
| 2018-09-30 | $0.00 10-K · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $0.00 10-K · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $0.00 10-K · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $1.40M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $1.40M derived: sum of 3 quarters · filed 2019-02-28 | $1.56M 10-K · filed 2019-02-28 |
| 2017-09-30 | $0.00 10-K · filed 2019-02-28 | $1.40M derived: sum of 2 quarters · filed 2019-02-28 | $1.56M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $1.40M 10-K · filed 2019-02-28 | $1.56M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $161.00K 10-K · filed 2019-02-28 | |||
| 2016-12-31 | $189.48M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |